Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been assigned a consensus rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $15.80.

Several brokerages have issued reports on ZURA. Leerink Partnrs raised shares of Zura Bio to a "strong-buy" rating in a research report on Monday, November 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zura Bio in a report on Wednesday, December 11th. Chardan Capital reduced their price objective on Zura Bio from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, November 8th. Leerink Partners began coverage on Zura Bio in a research note on Monday, November 4th. They issued an "outperform" rating and a $15.00 target price on the stock. Finally, HC Wainwright restated a "neutral" rating and set a $5.00 price target on shares of Zura Bio in a research note on Tuesday, December 24th.

Zura Bio Stock Performance

Shares of ZURA traded up $0.05 during mid-day trading on Thursday, reaching $1.55. 177,257 shares of the company's stock were exchanged, compared to its average volume of 495,439. The business's fifty day simple moving average is $2.07 and its 200-day simple moving average is $3.22. Zura Bio has a 52-week low of $1.35 and a 52-week high of $6.35.

Insider Activity

In other news, Director Parvinder Thiara sold 1,001,633 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 22.10% of the company's stock.

Institutional Trading of Zura Bio

A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock valued at $3,706,000 after acquiring an additional 377,545 shares during the last quarter. Barclays PLC lifted its holdings in Zura Bio by 777.1% in the 3rd quarter. Barclays PLC now owns 64,061 shares of the company's stock valued at $260,000 after purchasing an additional 56,757 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Zura Bio during the 3rd quarter worth about $71,000. Braidwell LP purchased a new stake in shares of Zura Bio during the third quarter worth about $10,040,000. Finally, State Street Corp grew its holdings in shares of Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company's stock worth $1,604,000 after buying an additional 127,300 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.